Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932385 | 1.00 | RORC (0.43) | RORCMMP3PAX8FFAR4KDM1A | |
| Trifluoroacetic Acid SCHEMBL23932458 | 0.92 | TPSAB1 (0.42) | RORCMMP3FFAR4 | |
| SCHEMBL23960572 | 0.90 | RORC (0.37) | RORCPAX8 | |
| SCHEMBL23932369 | 0.90 | RORC (0.37) | RORCPAX8 | |
| SCHEMBL23932460 | 0.85 | MMP3 (0.41) | RORCMMP3FFAR4ALDH1A1HRH3 | |
| SCHEMBL23960553 | 0.83 | PDE4B (0.35) | RORCPAX8KDM1A | |
| SCHEMBL26078655 | 0.83 | PDE4B (0.35) | RORCPAX8KDM1A | |
| SCHEMBL23932328 | 0.83 | PDE4B (0.35) | RORCPAX8KDM1A | |
| SCHEMBL23960607 | 0.79 | NAMPT (0.42) | RORCMMP3 | |
| SCHEMBL30151664 | 0.79 | NAMPT (0.42) | RORCMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2021216592-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | RORC 2781/4885MMP3 79/4885PAX8 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.